Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-12-30
DOI
10.1038/s41598-019-56900-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation
- (2019) Adrian C. Jaramillo et al. LEUKEMIA RESEARCH
- Febuxostat-induced acute liver injury
- (2016) Matt Bohm et al. HEPATOLOGY
- Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations
- (2016) Hiroshi Miyata et al. Frontiers in Pharmacology
- FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk
- (2015) M. Spina et al. ANNALS OF ONCOLOGY
- Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database
- (2015) Yukiya Suzuki et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug–Drug Interactions in Vivo
- (2015) Selvi Durmus et al. MOLECULAR PHARMACEUTICS
- Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors
- (2014) David J. Reeves et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
- (2014) Wei-Chien Huang et al. PLoS One
- Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells
- (2013) Maria Ulvestad et al. BIOCHEMICAL PHARMACOLOGY
- Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals
- (2013) MEI ZHANG et al. Experimental and Therapeutic Medicine
- High-dose methotrexate in adult oncology patients: A case-control study assessing the risk association between drug interactions and methotrexate toxicity
- (2013) April J Chan et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins
- (2012) H. H. J. Gerets et al. CELL BIOLOGY AND TOXICOLOGY
- Influence of Human OATP1B1, OATP1B3, and OATP1A2 on the Pharmacokinetics of Methotrexate and Paclitaxel in Humanized Transgenic Mice
- (2012) E. van de Steeg et al. CLINICAL CANCER RESEARCH
- Case Definition and Phenotype Standardization in Drug-Induced Liver Injury
- (2011) G P Aithal et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Hepatotoxicity related to antirheumatic drugs
- (2011) Guruprasad P. Aithal Nature Reviews Rheumatology
- The Tumor Lysis Syndrome
- (2011) Scott C. Howard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quantitative signal detection using spontaneous ADR reporting
- (2009) A. Bate et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy
- (2008) Kunihiro Suzuki et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the In vivo Elimination of Methotrexate and its Main Toxic Metabolite 7-hydroxymethotrexate
- (2008) M. L.H. Vlaming et al. CLINICAL CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started